Sustained Delivery of RhoA activator for Treatment of Intervertebral Disc Degeneration

Columbia University Health Sciences, New York NY

Investigators

Linked publications, trials & patents

Abstract

This application is for a diversity supplement for a post-baccalaureate student who will be doing a year-long mentored research experience in the lab of the PI, Dr. Nadeen Chahine’s on a research project related to this NIH parent award. The candidate’s career goals are to become a physician scientist, specializing in orthopedics and musculoskeletal medicine. The candidate is an engineer (U.S. citizen) from an underrepresented race/ethnic group in STEM, as defined by the guidelines provided by NSF and NIH on workforce diversity. The candidate’s research training in orthopedic research at Columbia University enhances the diversity of the biomedical research workforce. The diversity supplement project will examine the effects of aging and degeneration on RhoA signaling and actomyosin contractility of IVD. The diversity supplement project is a direct extension of the scope of the parent R21 project on sustained delivery of RhoA activator for treatment of intervertebral disc (IVD) degeneration. This project is expected to advance therapeutic treatment of disc degeneration and back pain.